^
BIOMARKER:

BCL2 overexpression

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
Lymphoma Hub - 3 weeks
BCL2 overexpression
Multiple Myeloma
venetoclax
Sensitive: B - Late Trials
BCL2 overexpression
Multiple Myeloma
venetoclax + carfilzomib
Sensitive: C2 – Inclusion Criteria
BCL2 overexpression
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
BCL2 overexpression
AML
7+3 (DAC)
Resistant: C3 – Early Trials
BCL2 overexpression
SCCHN
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
BCL2 overexpression
NSCLC
AZD2811
Resistant: D – Preclinical
BCL2 overexpression
HL
venetoclax
Resistant: D – Preclinical
BCL2 overexpression
Diffuse Large B Cell Lymphoma
APG-2575
Sensitive: D – Preclinical
BCL2 overexpression
AML
IACS-010759
Resistant: D – Preclinical
BCL2 overexpression
Multiple Myeloma
bortezomib + A-1331852
Sensitive: D – Preclinical
BCL2 overexpression
AML
venetoclax + AZD5991
Sensitive: D – Preclinical
BCL2 overexpression
Lung Cancer
osimertinib
Sensitive: D – Preclinical
BCL2 overexpression
Lung Cancer
afatinib
Sensitive: D – Preclinical
BCL2 overexpression
Lung Cancer
venetoclax + gefitinib
Sensitive: D – Preclinical
BCL2 overexpression
Lung Cancer
gefitinib + ABT 263
Sensitive: D – Preclinical